Xospata (Gilteritinib Fumarate) Patent Expiration, LOE Window & CMS Spending

Xospata (Gilteritinib Fumarate) by Astellas Pharma: FDA Orange Book core substance LOE 2032-11-28 (last listed 2036-07-01), 0 AB generics, $124.6M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAstellas Pharma
FDA Application & PathwayN211349 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2032-11-28
Last Listed Patent or Exclusivity Date2036-07-01
Orange Book Patents (*PED Extensions)8 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$124.6M
2024 Medicare Part D Spend$106.4M
2024 Medicaid Spend$18.2M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Astellas Pharma across sibling Meru public-data platforms.